LENZ · Insider Trading
LENZ Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by LENZ officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-15 | Frederic Guerard | Director | A | +22,100 deriv. | — |
| 2026-06-15 | James W McCollum | Director | A | +22,100 deriv. | — |
| 2026-06-15 | Shelley B Thunen | Director | A | +22,100 deriv. | — |
| 2026-06-15 | Kimberlee C Drapkin | Director | A | +22,100 deriv. | — |
| 2026-06-15 | Zachary Scheiner | Director | A | +22,100 deriv. | — |
| 2026-06-15 | Jeffrey P. George | Director | A | +22,100 deriv. | — |
| 2026-06-15 | RA Capital Nexus Fund II, L.P. | Director | A | +110,500 deriv. | — |
| 2026-03-30 | Evert B. Schimmelpennink | President, CEO and Secretary | Buy | +28,089 | +$251.41K |
| 2026-03-30 | Jeffrey P. George | Director | Buy | +5,592 | +$49.89K |
| 2026-03-30 | Daniel R. Chevallard | Chief Financial Officer | Buy | +7,500 | +$64.28K |
| 2026-01-06 | Marc Odrich | Chief Medical Officer | A | +98,200 deriv. | — |
| 2026-01-06 | Shawn Olsson | Chief Commercial Officer | A | +98,200 deriv. | — |
| 2026-01-06 | Daniel R. Chevallard | Chief Financial Officer | A | +98,200 deriv. | — |
| 2026-01-06 | Evert B. Schimmelpennink | President, CEO and Secretary | A | +358,100 deriv. | — |
| 2025-11-19 | Shawn Olsson | Chief Commercial Officer | MIXED | — | −$240.22K |
| 2025-11-10 | James W McCollum | Director | Buy | +10,500 | +$239.28K |
| 2025-11-07 | Daniel R. Chevallard | Chief Financial Officer | Buy | +2,198 | +$50.02K |
| 2025-10-02 | Versant Vantage II GP-GP, LLC | 10%+ Owner | Sell | −2,024,766 | −$93.17M |
| 2025-09-22 | Versant Venture Capital VII, L.P. | 10%+ Owner | Sell | −1,217,736 | −$51.43M |
| 2025-08-26 | Versant Venture Capital VI, L.P. | 10%+ Owner | Sell | −1,692,846 | −$66.82M |
| 2025-08-19 | Versant Venture Capital VII, L.P. | 10%+ Owner | Sell | −2,346,417 | −$92.30M |
| 2025-07-14 | Versant Venture Capital VI, L.P. | 10%+ Owner | Sell | −1,722,384 | −$58.56M |
| 2025-07-01 | Versant Vantage II GP, L.P. | 10%+ Owner | Sell | −1,800,000 | −$54.84M |
| 2025-06-20 | Versant Vantage II GP, L.P. | 10%+ Owner | Sell | −3,013,209 | −$90.97M |
| 2025-06-12 | Versant Venture Capital VI, L.P. | 10%+ Owner | Sell | −3,150,000 | −$91.35M |
| 2025-06-11 | Zachary Scheiner | Director | A | +13,500 deriv. | — |
| 2025-06-11 | Jeffrey P. George | Director | A | +13,500 deriv. | — |
| 2025-06-11 | James W McCollum | Director | A | +13,500 deriv. | — |
| 2025-06-11 | Frederic Guerard | Director | A | +13,500 deriv. | — |
| 2025-06-11 | Shelley B Thunen | Director | A | +13,500 deriv. | — |
| 2025-06-11 | Kimberlee C Drapkin | Director | A | +13,500 deriv. | — |
| 2025-06-11 | RA Capital Nexus Fund II, L.P. | Director | A | +67,500 deriv. | — |
| 2025-04-09 | Shawn Olsson | Chief Commercial Officer | M | +1,400 | +$2.91K |
| 2025-03-07 | Evert B. Schimmelpennink | President, CEO and Secretary | M | +4,200 | +$4.37K |
| 2025-01-13 | Shawn Olsson | Chief Commercial Officer | A | +80,100 deriv. | — |
| 2025-01-13 | Daniel R. Chevallard | Chief Financial Officer | A | +70,444 deriv. | — |
| 2025-01-13 | Evert B. Schimmelpennink | President, CEO and Secretary | A | +279,100 deriv. | — |
| 2025-01-13 | Marc Odrich | Chief Medical Officer | A | +80,100 deriv. | — |
| 2024-12-17 | Shawn Olsson | Chief Commercial Officer | M | +3,333 | +$6.93K |
| 2024-07-23 | Evert B. Schimmelpennink | President, CEO and Secretary | M | +45,000 | +$46.80K |
| 2024-05-15 | Daniel R. Chevallard | Chief Financial Officer | Buy | +3,188 | +$49.99K |
| 2024-05-14 | James W McCollum | Director | Buy | +31,332 | +$501.09K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Versant Vantage II GP, L.P. | 10%+ Owner | 2,609,437 | $8.40M |
| Versant Venture Capital VI, L.P. | 10%+ Owner | 2,299,292 | $7.40M |
| Versant Venture Capital VII, L.P. | 10%+ Owner | 2,060,248 | $6.63M |
| Versant Vantage II GP-GP, LLC | 10%+ Owner | 1,898,092 | $6.11M |
| James W McCollum | Director | 631,099 | $2.03M |
| Evert B. Schimmelpennink | President, CEO and Secretary | 77,289 | $248.87K |
| Daniel R. Chevallard | Chief Financial Officer | 12,886 | $41.49K |
| Jeffrey P. George | Director | 5,592 | $18.01K |
| Shawn Olsson | Chief Commercial Officer | 4,733 | $15.24K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LENZ quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.